The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Systemic Lupus Erythematosus (SLE)
Cutaneous Lupus Erythematosus (CLE)
Interventions
DRUG:
HC022
DRUG:
Placebo
Sponsor
HC Biopharma Inc.